B+
Bull case
25%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
SNES
SenesTechFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 e-commerce and subscription growth, July momentum and the announced Grove channel could support a larger recurring-sales base if repeat purchases and gross margin persist. This is a conditional operating case, not company guidance.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Evolve and ContraPest are commercial rodent-control products; a generic clinical-trial or biotech-peer thesis would misstate the operating exposure. Company release.
Momentum
85
Value
41
Sentiment
16
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.62 · Bull $0.95 · Bear $0.30Analysis 2026-09-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-29 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-29
Investment thesis
As of 2026-10-29
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-29. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.50
Why
Momentum85 · Δ7d -
Value41 · Δ7d -0.1
Sentiment16 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Evolve and ContraPest are commercial rodent-control products; a generic clinical-trial or biotech-peer thesis would misstate the operating exposure. Company release.
- • First-half operating cash use rose to $3.64 million from $2.71 million a year earlier despite reported revenue growth. 10-Q.
- • Reported Q2 direct B2B revenue fell to $259,000 from $460,000 a year earlier; the company attributed part of the comparison to prior-period bulk and distributor orders.
Catalyst clock
2026-12-31
Grove marketplace launch and sales conversion
Lead driver: Value · See fundamentals
Momentum
85
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
16
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 84.6 / Value 40.7 / Sentiment 16.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-29. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.62
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.30
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$5.48M
Beta
0.22
Shares Out
5.42M
P/E (TTM) · Derived
-0.5
P/S (TTM)
5.08
P/FCF (TTM) · Derived
-0.77
Rev YoY
+23.2%
EPS YoY
-60.4%
Gross Margin
+61.5%
Op Margin
-303.7%
Net Debt
-$5.89M
Current Ratio
6.78
As of 2026-10-29 • Updated nightlySource: Internal modelMethods & Data